Up 13%: Why is everyone buying Pro Medicus shares this week?

The ASX healthcare shares jumped another 3% on Wednesday.

Pro Medicus Ltd (ASX: PME) shares closed the day up around 3% on Wednesday afternoon, at $184.83.

The increase means the shares have now jumped 13% over the past week alone. The latest rally has helped recoup some of the losses shed by the company over the past 12 months. But they're still down 17% for the year-to-date and 36% lower than 12 months ago.

Happy businessman fist pumping while looking at a tablet.

Image source: Getty Images

Why is everyone rushing to buy Pro Medicus shares this week?

The ASX healthcare company has come into focus this week after it announced two new seven-year contract wins.

On Monday, Pro Medicus announced its wholly owned US subsidiary, Visage Imaging, had signed a A$24 million contract with Billings Clinic – Logan Health in the US. The implementation will see Visage 7's entire platform integrated, including image distribution within the client's electronic health record system. Rollout planning is underway, aiming for a go-live date in early 2027.

The announcement was followed by news of a second contract deal on Wednesday. Pro Medicus announced a A$43 million contract with Virtua Health, also in the United States, for a unified imaging platform comprising Visage 7 Viewer, Workflow, Open Archive, and Cardiology products. Planning is underway and with a go-live date in around the second or third quarter of the 2027 calendar year. 

The announcements have clearly been well received by investors. 

The new contract wins continue a strong run of major client acquisitions and contract renewals this year.

They also come at a time when the broader healthcare sector is continuing to rebound after a difficult first-half to the calendar year.

Are the shares a buy, sell, or hold after the latest rally?

Most experts are still very optimistic about the outlook for Pro Medicus shares over the next 12 months.

TradingView data shows that the majority (nine out of 15) have a buy/strong buy rating on the shares. Another five rate the stock a hold, and one has a strong sell rating.

The average $212.74 target price sits around 15% above the trading price at the time of writing, implying a decent upside ahead over the next 12 months.

Some are even more optimistic and forecast the shares to jump up to 35% higher to $250 each within the next year, at the time of writing.

Citi recently renewed its buy rating on the shares with a $225 target.

The team at Morgans also think Pro Medicus shares are in the buy zone. They upgraded their rating to a buy with a $230 price target following its contract wins. The team commented that while the individual contracts in FY27 are modest, they're consistent in size, term, and scope. This helps to broaden the company's pipeline beyond large integrated delivery networks.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »